PT - JOURNAL ARTICLE AU - Hu, Zicheng AU - van der Ploeg, Kattria AU - Chakraborty, Saborni AU - Arunachalam, Prabhu AU - Mori, Diego Martinez AU - Jacobson, Karen B. AU - Bonilla, Hector AU - Parsonnet, Julie AU - Andrews, Jason AU - Hedlin, Haley AU - de la Parte, Lauren AU - Dantzler, Kathleen AU - Ty, Maureen AU - Tan, Gene S AU - Blish, Catherine A. AU - Takahashi, Saki AU - Rodriguez-Barraquer, Isabel AU - Greenhouse, Bryan AU - Butte, Atul J. AU - Singh, Upinder AU - Pulendran, Bali AU - Wang, Taia T. AU - Jagannathan, Prasanna TI - Early immune responses have long-term associations with clinical, virologic, and immunologic outcomes in patients with COVID-19 AID - 10.1101/2021.08.27.21262687 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.27.21262687 4099 - http://medrxiv.org/content/early/2021/08/29/2021.08.27.21262687.short 4100 - http://medrxiv.org/content/early/2021/08/29/2021.08.27.21262687.full AB - The great majority of SARS-CoV-2 infections are mild and uncomplicated, but some individuals with initially mild COVID-19 progressively develop more severe symptoms. Furthermore, mild to moderate infections are an important contributor to ongoing transmission. There remains a critical need to identify host immune biomarkers predictive of clinical and virologic outcomes in SARS-CoV-2-infected patients. Leveraging longitudinal samples and data from a clinical trial of Peginterferon Lambda for treatment of SARS-CoV-2 infected outpatients, we used host proteomics and transcriptomics to characterize the trajectory of the immune response in COVID-19 patients within the first 2 weeks of symptom onset. We define early immune signatures, including plasma levels of RIG-I and the CCR2 ligands (MCP1, MCP2 and MCP3), associated with control of oropharyngeal viral load, the degree of symptom severity, and immune memory (including SARS-CoV-2-specific T cell responses and spike (S) protein-binding IgG levels). We found that individuals receiving BNT162b2 (Pfizer–BioNTech) vaccine had similar early immune trajectories to those observed in this natural infection cohort, including the induction of both inflammatory cytokines (e.g. MCP1) and negative immune regulators (e.g. TWEAK). Finally, we demonstrate that machine learning models using 8-10 plasma protein markers measured early within the course of infection are able to accurately predict symptom severity, T cell memory, and the antibody response post-infection.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04331899Funding StatementSupport for the study was provided from NIH/NIAID (U01 AI150741-01S1 to ZH, ST, IRB, BG, TW, and PJ), Stanford Innovative Medicines Accelerator, and NIH/NIDA DP1DA046089. The Lambda clinical trial was funded by anonymous donors to Stanford University, and Peginterferon Lambda provided by Eiger BioPharmaceuticals. The funders had no role in data collection and analysis or the decision to publish. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of Stanford University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe will be available upon request.